Forced degradation studies: an essential tool for the formulation development of vaccines

Forced degradation studies are typically conducted during the early development phase of vaccine candidates to obtain information on potential degradation pathways, support analytical methods development, and identify potential vaccine stabilizers and optimal condi- tions for long-term storage. The regulatory guidelines for forced degradation regarding biolog- ics have few to no procedural instructions on how to approach forced degradation studies. In this review, we provide an overview of methods used to study forced degradation in vaccines, mechanisms of degradation, analytical methodology, forced degradation examples conducted for vaccine products, and a summary of stabilizers that are used to influence the results of new vaccine candidates.

[1]  Ronald T Borchardt,et al.  Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. , 2006, Journal of pharmaceutical sciences.

[2]  N. Pujar,et al.  Study of Detergent‐Mediated Liberation of Hepatitis B Virus‐like Particles from S. cerevisiae Homogenate: Identifying a Framework for the Design of Future‐Generation Lipoprotein Vaccine Processes , 2008, Biotechnology progress.

[3]  David R. Olsen,et al.  Stabilization of proteins by recombinant human gelatins. , 2007, Journal of pharmaceutical sciences.

[4]  J. Haensler Liposomal adjuvants: preparation and formulation with antigens. , 2010, Methods in molecular biology.

[5]  A. Fane,et al.  Some factors determining protein aggregation during ultrafiltration. , 1993, Biotechnology and bioengineering.

[6]  M. Hanna,et al.  Time-dependent aggregation of reconstituted BCG vaccine. , 1994, The Journal of urology.

[7]  Bernard Metz,et al.  Reduction of animal use in human vaccine quality control: opportunities and problems. , 2002, Vaccine.

[8]  W. Habig Potency testing of bacterial vaccines for human use. , 1993, Veterinary Microbiology.

[9]  M. Manning,et al.  Flow imaging: moving toward best practices for subvisible particle quantitation in protein products. , 2013, Journal of pharmaceutical sciences.

[10]  C. Wallis,et al.  Effect of pH on Thermal Stabilization of Oral Poliovirus Vaccine by Magnesium Chloride , 1963, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[11]  M. Corbel,et al.  Effect of physico-chemical modification on the immunogenicity of Haemophilus influenzae type b oligosaccharide-CRM(197) conjugate vaccines. , 2001, Vaccine.

[12]  Andrea Hanefeld,et al.  Relevant shaking stress conditions for antibody preformulation development. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[13]  H. Doyle,et al.  Altered immunogenicity of isoaspartate containing proteins , 2007, Autoimmunity.

[14]  B. Yan,et al.  Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. , 2009, Journal of pharmaceutical sciences.

[15]  D. Volkin,et al.  Formulation, stability, and delivery of live attenuated vaccines for human use. , 1999, Critical reviews in therapeutic drug carrier systems.

[16]  M. Mosca,et al.  Effect of membrane composition on lipid oxidation in liposomes. , 2011, Chemistry and physics of lipids.

[17]  Stephen Naylor,et al.  The role of mass spectrometry in vaccine development. , 2001, Vaccine.

[18]  S. Ausar,et al.  High-throughput screening of stabilizers for Respiratory Syncytial Virus: Identification of stabilizers and their effects on the conformational thermostability of viral particles , 2007, Human vaccines.

[19]  T. Krell,et al.  Characterization of different strains of poliovirus and influenza virus by differential scanning calorimetry , 2005, Biotechnology and applied biochemistry.

[20]  P. Kolhe,et al.  Protein and solute distribution in drug substance containers during frozen storage and post‐thawing: A tool to understand and define freezing–thawing parameters in biotechnology process development , 2011, Biotechnology progress.

[21]  L. Chedid,et al.  Current status of immunological adjuvants. , 1986, Annual review of immunology.

[22]  C Russell Middaugh,et al.  Physical stabilization of Norwalk virus-like particles. , 2008, Journal of pharmaceutical sciences.

[23]  G. Marius Clore,et al.  Recombinant-derived interleukin-1α stabilized against specific deamidation , 1987 .

[24]  S. Singh,et al.  Effect of antimicrobial preservatives on partial protein unfolding and aggregation. , 2013, Journal of pharmaceutical sciences.

[25]  S. Ausar,et al.  Analysis of the thermal and pH stability of human respiratory syncytial virus. , 2005, Molecular pharmaceutics.

[26]  C. Jones,et al.  Physicochemical and immunological studies on the stability of free and microsphere-encapsulated tetanus toxoid in vitro. , 1996, Vaccine.

[27]  Hennessey Jp,et al.  Simultaneous evaluation of molecular size and antigenic stability of PNEUMOVAX 23, a multivalent pneumococcal polysaccharide vaccine. , 2000 .

[28]  C. Frasch Preparation of bacterial polysaccharide-protein conjugates: analytical and manufacturing challenges. , 2009, Vaccine.

[29]  Tim J Kamerzell,et al.  Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. , 2011, Advanced drug delivery reviews.

[30]  Nigel Jenkins,et al.  Post-translational Modifications of Recombinant Proteins: Significance for Biopharmaceuticals , 2008, Molecular biotechnology.

[31]  Michael J. Pikal,et al.  Protein Stability During Freezing: Separation of Stresses and Mechanisms of Protein Stabilization , 2007, Pharmaceutical development and technology.

[32]  P. Domingues,et al.  Separation of peroxidation products of diacyl-phosphatidylcholines by reversed-phase liquid chromatography-mass spectrometry. , 2005, Biomedical chromatography : BMC.

[33]  R. Sitrin,et al.  Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminum hydroxide. , 1999, Vaccine.

[34]  D. Brems,et al.  Inverse Relationship of Protein Concentration and Aggregation , 2002, Pharmaceutical Research.

[35]  R. K. Evans,et al.  Development of stable liquid formulations for adenovirus-based vaccines. , 2004, Journal of pharmaceutical sciences.

[36]  Kevin Harper,et al.  Application of extrinsic fluorescence spectroscopy for the high throughput formulation screening of aluminum-adjuvanted vaccines. , 2011, Journal of pharmaceutical sciences.

[37]  S. Ausar,et al.  Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvants. , 2012, Vaccine.

[38]  A. Klibanov,et al.  The secondary structure and aggregation of lyophilized tetanus toxoid. , 1996, Journal of pharmaceutical sciences.

[39]  P. Jurkiewicz,et al.  Biophysics of lipid bilayers containing oxidatively modified phospholipids: insights from fluorescence and EPR experiments and from MD simulations. , 2012, Biochimica et biophysica acta.

[40]  A. Fane,et al.  Effect of membrane morphology and operation on protein deposition in ultrafiltration membranes , 1995, Biotechnology and bioengineering.

[41]  A. Gronenborn,et al.  Recombinant-derived interleukin-1 alpha stabilized against specific deamidation. , 1987, Protein Engineering.

[42]  Leonard A. Smith,et al.  Improved formulation of a recombinant ricin A-chain vaccine increases its stability and effective antigenicity. , 2007, Vaccine.

[43]  C. Muller,et al.  Humoral immune responses to a protective peptide-conjugate against measles after different prime-boost regimens. , 2004, Vaccine.

[44]  Hanns-Christian Mahler,et al.  Forced degradation of therapeutic proteins. , 2012, Journal of pharmaceutical sciences.

[45]  S. Joshi,et al.  Spectroscopic methods for the physical characterization and formulation of nonviral gene delivery systems. , 2008, Methods in molecular biology.

[46]  J. Carpenter,et al.  Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry. , 2009, Journal of pharmaceutical sciences.

[47]  Brian M. Murphy,et al.  Stability of Protein Pharmaceuticals: An Update , 2010, Pharmaceutical Research.

[48]  B. Chang,et al.  Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. , 1996, Journal of pharmaceutical sciences.

[49]  T. Vedvick,et al.  Conformational Stability and Disassembly of Norwalk Virus-like Particles , 2006, Journal of Biological Chemistry.

[50]  J L Cleland,et al.  Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. , 1998, Journal of pharmaceutical sciences.

[51]  S. Singh,et al.  An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. , 2010, Journal of pharmaceutical sciences.

[52]  Dexiang Chen,et al.  Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability. , 2011, Journal of pharmaceutical sciences.

[53]  G. Sanyal,et al.  Analysis of vaccine stability. , 1996, Developments in biological standardization.

[54]  C. Spickett,et al.  Chemistry of phospholipid oxidation. , 2012, Biochimica et biophysica acta.

[55]  C. Hutcheon,et al.  Physiochemical and functional characterization of antigen proteins eluted from aluminum hydroxide adjuvant. , 2006, Vaccine.

[56]  S. Joshi,et al.  Biophysical and stabilization studies of the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. , 2009, Molecular Pharmaceutics.

[57]  M. Festing Reduction in animal use in the production and testing of biologicals. , 1999, Developments in biological standardization.

[58]  R. Borchardt,et al.  Chemical Pathways of Peptide Degradation. I. Deamidation of Adrenocorticotropic Hormone , 1990, Pharmaceutical Research.

[59]  C. Russell Middaugh,et al.  Stabilization of measles virus for vaccine formulation , 2008, Human vaccines.

[60]  A. Hinman,et al.  Haemophilus influenzae type B conjugate vaccine , 1988 .

[61]  L. Peek,et al.  Effects of Adsorption to Aluminum Salt Adjuvants on the Structure and Stability of Model Protein Antigens* , 2005, Journal of Biological Chemistry.

[62]  Hanns-Christian Mahler,et al.  Protein aggregation: pathways, induction factors and analysis. , 2009, Journal of pharmaceutical sciences.

[63]  S. Joshi,et al.  Physical characterization and formulation development of a recombinant pneumolysoid protein-based pneumococcal vaccine. , 2013, Journal of pharmaceutical sciences.

[64]  John F. Carpenter,et al.  Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation , 2003, Pharmaceutical Research.

[65]  Vincent J. Sullivan,et al.  Evaluation of the effect of syringe surfaces on protein formulations. , 2011, Journal of pharmaceutical sciences.

[66]  Diwakar Shukla,et al.  Understanding the synergistic effect of arginine and glutamic acid mixtures on protein solubility. , 2011, The journal of physical chemistry. B.

[67]  M. Slifka,et al.  Development of a new hydrogen peroxide–based vaccine platform , 2012, Nature Medicine.

[68]  Gideon Kersten,et al.  The Potential of Physicochemical and Immunochemical Assays to Replace Animal Tests in the Quality Control of Toxoid Vaccines , 2007, Alternatives to laboratory animals : ATLA.

[69]  D. Volkin,et al.  Degradative covalent reactions important to protein stability , 1997, Molecular biotechnology.

[70]  Debra Kristensen,et al.  Opportunities and challenges of developing thermostable vaccines , 2009, Expert review of vaccines.

[71]  S. Joshi,et al.  Multidimensional methods for the formulation of biopharmaceuticals and vaccines. , 2011, Journal of pharmaceutical sciences.

[72]  R. Borchardt,et al.  Stability of Protein Pharmaceuticals , 1989, Pharmaceutical Research.

[73]  Bruce A Kerwin,et al.  Protect from light: photodegradation and protein biologics. , 2007, Journal of pharmaceutical sciences.

[74]  A. Rosenberg,et al.  Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.

[75]  R. Borchardt,et al.  Chemical Pathways of Peptide Degradation. VII. Solid State Chemical Instability of an Aspartyl Residue in a Model Hexapeptide , 1994, Pharmaceutical Research.

[76]  B Demple,et al.  Repair of oxidative damage to DNA: enzymology and biology. , 1994, Annual review of biochemistry.

[77]  J. Hennessey,et al.  Simultaneous evaluation of molecular size and antigenic stability of PNEUMOVAX 23, a multivalent pneumococcal polysaccharide vaccine. , 2000, Developments in Biologicals.

[78]  T. Hoover,et al.  Multiple asparagine deamidation of Bacillus anthracis protective antigen causes charge isoforms whose complexity correlates with reduced biological activity , 2007, Proteins.

[79]  Chung C. Hsu,et al.  Effect of high shear on proteins , 2000, Biotechnology and bioengineering.

[80]  S. N. Timasheff,et al.  Protein-solvent preferential interactions, protein hydration, and the modulation of biochemical reactions by solvent components , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[81]  R. Kennedy,et al.  Real time monitoring of antigenicity development of HBsAg virus-like particles (VLPs) during heat- and redox-treatment. , 2011, Biochemical and biophysical research communications.

[82]  T. Arakawa,et al.  Mechanisms of protein aggregation. , 2009, Current pharmaceutical biotechnology.

[83]  M. Longo,et al.  Trehalose maintains phase separation in an air-dried binary lipid mixture. , 2003, Biophysical journal.

[84]  R. Borchardt,et al.  Chemical Pathways of Peptide Degradation. III. Effect of Primary Sequence on the Pathways of Deamidation of Asparaginyl Residues in Hexapeptides , 1990, Pharmaceutical Research.

[85]  R. K. Evans,et al.  Analysis of plasmid DNA from a pharmaceutical perspective. , 1998, Journal of pharmaceutical sciences.

[86]  P. Hotez,et al.  Advances in vaccines against neglected tropical diseases , 2012, Human vaccines & immunotherapeutics.

[87]  A. Klibanov,et al.  Moisture‐induced aggregation of lyophilized proteins in the solid state , 1991, Biotechnology and bioengineering.

[88]  D. Volkin,et al.  Size and conformational stability of the hepatitis A virus used to prepare VAQTA, a highly purified inactivated vaccine. , 1997, Journal of pharmaceutical sciences.

[89]  B. Lina,et al.  A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly. , 2000, Biologicals : journal of the International Association of Biological Standardization.

[90]  Maya S. Salnikova,et al.  Influence of formulation pH and suspension state on freezing-induced agglomeration of aluminum adjuvants. , 2012, Journal of Pharmacy and Science.

[91]  J. Kuo,et al.  Replacement of a labile aspartyl residue increases the stability of human epidermal growth factor. , 1990, Biochemistry.

[92]  Jared S. Bee,et al.  Monoclonal antibody interactions with micro- and nanoparticles: adsorption, aggregation, and accelerated stress studies. , 2009, Journal of pharmaceutical sciences.

[93]  D. Pogocki,et al.  Conformational Flexibility Controls Proton Transfer between the Methionine Hydroxy Sulfuranyl Radical and the N-Terminal Amino Group in Thr−(X)n−Met Peptides , 2001 .

[94]  D. Volkin,et al.  Preformulation studies--The next advance in aluminum adjuvant-containing vaccines. , 2010, Vaccine.

[95]  C. Wiethoff,et al.  Thermal stability of vaccines. , 2003, Journal of pharmaceutical sciences.